Rise of Cardio‐Oncology

To participate in this activity, please:

Course Credit:

1.00 AMA PRA Category 1 CreditTM
1.00 CA-BRN Contact Hour


Opens: 2022-11-10
Closes: 2022-12-10

Target Audience:

Accreditation and Certification

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Annenberg Center for Health Sciences

All members of the Eisenhower Health Education Committee have no relevant financial relationships to disclose

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Eric H Yang, MD, FACC, FASE

    Associate Clinical Professor of Medicine
    David Geffen School of Medicine at UCLA
    Associate Program Director,
    UCLA/Olive View/West LAVA Health Care System
    Cardiovascular Diseases Fellowship
    Director and Founder, UCLA Cardio-oncology Program
    University of California, Los Angeles
    Los Angeles, California


This course has no downloads at this time.

Learning Objectives

  • Describe the incidence of cardiovascular events that occur with cancer and cancer treatments, and how it can affect overall short and long term comorbidity and mortality
  • Review expert consensus statements and recent clinical trials on diagnosing, treating, and managing cardiotoxicity from both historical (i.e. anthracyclines, anti-HER2) and novel cancer treatment agents (i.e. VEGF[1]inhibitors, immunotherapy)
  • Emphasize the importance of multidisciplinary discussions on management of cancer patients and survivors with complex cardiovascular disease requiring invasive treatment between cardiologists, oncologists, cardiothoracic surgeons, and cardio-oncologists

Faculty Disclosures

Eric H Yang, MD, FACC, FASE

Consultant: Edwards Lifesciences, Pfizer
Research Support: Boehringer Ingelheim, CSL Behring, Eli Lilly